Patents by Inventor Amin Hajitou
Amin Hajitou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101628Abstract: The present invention provides phagemid vectors and associated phagemid particles for cancer treatment, and in particular, to the use of novel phagemid particles and associated expression systems for the treatment, prevention, amelioration, or management of cancer. In particular, the invention relates to the use of phagemid particles and expression systems for the delivery of transgenes encoding cytokines, for the treatment, prevention, amelioration, or management of cancer. The invention also extends to the use of phagemid particles and expression systems for the delivery of transgenes, and for the combination of such treatment with the use of adoptively transferred T cells, for the treatment, prevention, amelioration, or management of cancer.Type: ApplicationFiled: September 22, 2023Publication date: March 28, 2024Applicant: Imperial College Innovations LimitedInventors: Amin Hajitou, Keittisak Suwan, Mariam Albahrani, Sajee Waramit
-
Publication number: 20240050580Abstract: In one aspect, the present disclosure relates to tumor associated macrophage (TAM) targeting peptide. In another aspect, the present disclosure relates to a method of targeting a TAM in a subject, the method comprising administering to the subject a TAM targeting peptide attached to and/or displayed on the surface of a solid particle. In yet another aspect, the present disclosure relates to a method of treating a tumor infiltrated with a TAM in a subject, the method comprising administering to the subject a TAM targeting peptide attached to and/or displayed on the surface of a solid particle.Type: ApplicationFiled: December 20, 2021Publication date: February 15, 2024Applicants: Rutgers, The State University of New Jersey, Board of Regents, The University of Texas SystemInventors: Renata Pasqualini, Wadih Arap, Fernanda I. Staquicini, Amin Hajitou, Wouter Driessen, Daniela Staquicini, Bettina Proneth
-
Patent number: 11820792Abstract: The present invention provides phagemid vectors and associated phagemid particles for cancer treatment, and in particular, to the use of novel phagemid particles and associated expression systems for the treatment, prevention, amelioration, or management of cancer. In particular, the invention relates to the use of phagemid particles and expression systems for the delivery of transgenes encoding cytokines, for the treatment, prevention, amelioration, or management of cancer. The invention also extends to the use of phagemid particles and expression systems for the delivery of transgenes, and for the combination of such treatment with the use of adoptively transferred T cells, for the treatment, prevention, amelioration, or management of cancer.Type: GrantFiled: April 24, 2018Date of Patent: November 21, 2023Assignee: Imperial College Innovations LimitedInventors: Amin Hajitou, Keittisak Suwan, Mariam Albahrani, Sajee Waramit
-
Publication number: 20230265452Abstract: The invention provides hybrid and recombinant phagemid vectors for expressing a transgene in a target cell transduced with the vector. A recombinant phagemid particle comprises at least one transgene expression cassette which encodes an agent which exerts a biological effect on the target cell, characterised in that the phagemid particle comprises a genome which lacks at least 50% of its bacteriophage genome. The invention extends to the use of such phagemid expression systems as a research tool, and for the delivery of transgenes in a variety of gene therapy applications, DNA and/or peptide vaccine delivery and imaging techniques. The invention extends to in vitro, in vivo or in situ methods for producing viral vectors, such as recombinant adeno-associated viruses (rAAV) or lentivirus vectors (rLV), and to genetic constructs used in such methods.Type: ApplicationFiled: September 29, 2022Publication date: August 24, 2023Applicant: IMPERIAL COLLEGE INNOVATIONS LIMITEDInventors: Amin Hajitou, Paladd Asavarut, Teerapong Yata
-
Patent number: 11603540Abstract: The invention provides hybrid and recombinant phagemid vectors for expressing a transgene in a target cell transduced with the vector. A recombinant phagemid particle comprises at least one transgene expression cassette which encodes an agent which exerts a biological effect on the target cell, characterised in that the phagemid particle comprises a genome which lacks at least 50% of its bacteriophage genome. The invention extends to the use of such phagemid expression systems as a research tool, and for the delivery of transgenes in a variety of gene therapy applications, DNA and/or peptide vaccine delivery and imaging techniques. The invention extends to in vitro, in vivo or in situ methods for producing viral vectors, such as recombinant adeno-associated viruses (rAAV) or lentivirus vectors (rLV), and to genetic constructs used in such methods.Type: GrantFiled: October 31, 2016Date of Patent: March 14, 2023Assignee: Imperial College Innovations LimitedInventors: Amin Hajitou, Paladd Asavarut, Teerapong Yata
-
Patent number: 10799542Abstract: The invention provides a recombinant targeted bacteriophage for expressing a transgene in a target cell transduced with the bacteriophage. The bacteriophage comprises a first nucleic acid sequence encoding a pill capsid minor coat protein that is configured to display a cell-targeting ligand for enabling delivery of the bacteriophage to a target cell, a second nucleic acid sequence encoding at least one pVIII capsid major coat protein that is configured to display a foreign peptide thereon, and a transgene which encodes a protein which exerts a biological effect on the target cell.Type: GrantFiled: May 12, 2014Date of Patent: October 13, 2020Assignee: Imperial College Innovations LimitedInventors: Amin Hajitou, Teerapong Yata
-
Publication number: 20200239535Abstract: The present invention provides phagemid vectors and associated phagemid particles for cancer treatment, and in particular, to the use of novel phagemid particles and associated expression systems for the treatment, prevention, amelioration, or management of cancer. In particular, the invention relates to the use of phagemid particles and expression systems for the delivery of transgenes encoding cytokines, for the treatment, prevention, amelioration, or management of cancer. The invention also extends to the use of phagemid particles and expression systems for the delivery of transgenes, and for the combination of such treatment with the use of adoptively transferred T cells, for the treatment, prevention, amelioration, or management of cancer.Type: ApplicationFiled: April 24, 2018Publication date: July 30, 2020Applicant: Imperial Innovations LimitedInventors: Amin Hajitou, Keittisak Suwan, Mariam Albahrani, Sajee Waramit
-
Patent number: 10471138Abstract: The invention provides a targeted bacteriophage-polymer complex comprising a recombinant targeted-bacteriophage and a cationic polymer. The complex has a net positive charge. The invention provides methods of preparing bacteriophages and complexes thereof, and to their uses for the delivery of transgenes in a variety of gene therapy applications.Type: GrantFiled: September 19, 2018Date of Patent: November 12, 2019Assignee: Imperial College Innovations LimitedInventors: Amin Hajitou, Teerapong Yata
-
Publication number: 20190083610Abstract: The invention provides a targeted bacteriophage-polymer complex comprising a recombinant targeted-bacteriophage and a cationic polymer. The complex has a net positive charge. The invention provides methods of preparing bacteriophages and complexes thereof, and to their uses for the delivery of transgenes in a variety of gene therapy applications.Type: ApplicationFiled: September 19, 2018Publication date: March 21, 2019Applicant: Imperial Innovations LimitedInventors: Amin Hajitou, Teerapong Yata
-
Publication number: 20180320200Abstract: The invention provides hybrid and recombinant phagemid vectors for expressing a transgene in a target cell transduced with the vector. A recombinant phagemid particle comprises at least one transgene expression cassette which encodes an agent which exerts a biological effect on the target cell, characterised in that the phagemid particle comprises a genome which lacks at least 50% of its bacteriophage genome. The invention extends to the use of such phagemid expression systems as a research tool, and for the delivery of transgenes in a variety of gene therapy applications, DNA and/or peptide vaccine delivery and imaging techniques. The invention extends to in vitro, in vivo or in situ methods for producing viral vectors, such as recombinant adeno-associated viruses (rAAV) or lentivirus vectors (rLV), and to genetic constructs used in such methods.Type: ApplicationFiled: October 31, 2016Publication date: November 8, 2018Applicant: IMPERIAL INNOVATIONS LIMITEDInventors: Amin Hajitou, Paladd Asavarut, Teerapong Yata
-
Publication number: 20180256740Abstract: Embodiments of the invention are generally directed to compositions and methods of delivering one or more transgene to a target cell, such as a tumor cell, in a site-specific manner to achieve enhanced expression and to constructs and compositions useful in such applications. In certain aspects, expression from a therapeutic nucleic acid may be assessed prior to administration of a treatment or diagnostic procedure to or on a subject.Type: ApplicationFiled: October 23, 2017Publication date: September 13, 2018Applicant: The Board of Regents of the University of Texas SystemInventors: Renata PASQUALINI, Wadih ARAP, Juri GELOVANI, Frank C. MARINI, III, Amin HAJITOU, Mian ALAUDDIN, Martin TREPEL
-
Publication number: 20170340684Abstract: The invention provides a recombinant targeted bacteriophage for expressing a transgene in a target cell transduced with the bacteriophage. The bacteriophage comprises a first nucleic acid sequence encoding a pill capsid minor coat protein that is configured to display a cell-targeting ligand for enabling delivery of the bacteriophage to a target cell, a second nucleic acid sequence encoding at least one pVIII capsid major coat protein that is configured to display a foreign peptide thereon, and a transgene which encodes a protein which exerts a biological effect on the target cell.Type: ApplicationFiled: May 12, 2014Publication date: November 30, 2017Applicant: IMPERIAL INNOVATIONS LIMITEDInventors: Amin Hajitou, Teerapong Yata
-
Patent number: 9827327Abstract: Embodiments of the invention are generally directed to compositions and methods of delivering one or more transgene to a target cell, such as a tumor cell, in a site-specific manner to achieve enhanced expression and to constructs and compositions useful in such applications. In certain aspects, expression from a therapeutic nucleic acid may be assessed prior to administration of a treatment or diagnostic procedure to or on a subject.Type: GrantFiled: February 23, 2012Date of Patent: November 28, 2017Assignee: The Board of Regents of the University of Texas SystemInventors: Renata Pasqualini, Wadih Arap, Juri Gelovani, Frank C. Marini, III, Amin Hajitou, Mian Alauddin, Martin Trepel
-
Publication number: 20160114032Abstract: The invention provides a targeted bacteriophage-polymer complex comprising a recombinant targeted-bacteriophage and a cationic polymer. The complex has a net positive charge. The invention provides methods of preparing bacteriophages and complexes thereof, and to their uses for the delivery of transgenes in a variety of gene therapy applications.Type: ApplicationFiled: May 12, 2014Publication date: April 28, 2016Applicant: Imperial Innovations LimitedInventors: Amin Hajitou, Teerapong Yata
-
Patent number: 8470528Abstract: Embodiments of the invention are generally directed to compositions and methods of delivering one or more transgene to a target cell, such as a tumor cell, in a site-specific manner to achieve enhanced expression and to constructs and compositions useful in such applications. In certain aspects, expression from a therapeutic nucleic acid may be assessed prior to administration of a treatment or diagnostic procedure to or on a subject.Type: GrantFiled: April 30, 2010Date of Patent: June 25, 2013Assignee: The Board of Regents of the University of Texas SystemInventors: Renata Pasqualini, Wadih Arap, Juri Gelovani, Frank C. Marini, III, Amin Hajitou, Mian Alauddin, Martin Trepel
-
Publication number: 20120178903Abstract: Embodiments of the invention are generally directed to compositions and methods of delivering one or more transgene to a target cell, such as a tumor cell, in a site-specific manner to achieve enhanced expression and to constructs and compositions useful in such applications. In certain aspects, expression from a therapeutic nucleic acid may be assessed prior to administration of a treatment or diagnostic procedure to or on a subject.Type: ApplicationFiled: February 23, 2012Publication date: July 12, 2012Inventors: Renata Pasqualini, Wadih Arap, Juri Gelovani, Amin Hajitou, Mian Alauddin, Martin Trepel
-
Publication number: 20100254896Abstract: Embodiments of the invention are generally directed to compositions and methods of delivering one or more transgene to a target cell, such as a tumor cell, in a site-specific manner to achieve enhanced expression and to constructs and compositions useful in such applications. In certain aspects, expression from a therapeutic nucleic acid may be assessed prior to administration of a treatment or diagnostic procedure to or on a subject.Type: ApplicationFiled: April 30, 2010Publication date: October 7, 2010Inventors: RENATA PASQUALINI, Wadih ARAP, Juri GELOVANI, Frank C. MARINI, III, Amin HAJITOU, Mian ALAUDDIN, Martin TREPEL
-
Publication number: 20070274908Abstract: Embodiments of the invention are generally directed to compositions and methods of delivering one or more transgene to a target cell, such as a tumor cell, in a site-specific manner to achieve enhanced expression and to constructs and compositions useful in such applications. In certain aspects, expression from a therapeutic nucleic acid may be assessed prior to administration of a treatment or diagnostic procedure to or on a subject.Type: ApplicationFiled: April 9, 2007Publication date: November 29, 2007Inventors: Renata Pasqualini, Wadih Arap, Juri Gelovani, Frank Marini, Amin Hajitou, Mian Alauddin, Martin Trepel